Tyr319
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr319  -  DNAM-1 (mouse)

Site Information
DDEKEDIyVNYPTFs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454845

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 2 ) , immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Disease tissue studied:
leukemia ( 1 ) , T cell leukemia ( 1 ) , melanoma skin cancer ( 1 ) , cancer, squamous cell carcinoma ( 1 )
Relevant cell line - cell type - tissue:
B16F10 ( 1 ) , CHO (fibroblast) ( 1 ) , Hepa 1-6 (epithelial) ( 1 ) , HNSCC ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , lymphocyte-spleen ( 2 ) , T lymphocyte ( 1 ) , YTS ( 2 )

Downstream Regulation
Effects of modification on DNAM-1:
molecular association, regulation ( 1 , 2 ) , protein degradation ( 1 ) , receptor internalization, induced ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cytoskeletal reorganization ( 2 )
Induce interaction with:
Cbl-b (human) ( 1 ) , GRB2 (mouse) ( 2 ) , PIK3R1 (mouse) ( 2 ) , VAV1 (mouse) ( 2 )

References 

1

Braun M, et al. (2020) CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. Immunity 53, 805-823.e15
33053330   Curated Info

2

Zhang Z, et al. (2015) DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med 212, 2165-82
26552706   Curated Info